Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Sanson

Showing results (171-180 of 290) with videos related to

Pageof 29
Sort By:
Neuro-Oncology|January 31, 2006
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastomaAlexandre Carpentier, Florence Laigle-Donadey, Sarah Zohar, et al.
Journal of Neuro-Oncology|June 15, 2019
Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastomaAntonin Dréan, Nolwenn Lemaire, Guillaume Bouchoux, et al.
International Journal of Cancer|December 14, 2007
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomasAhmed Idbaih, Yannick Marie, Carlo Lucchesi, et al.
Neuro-Oncology|March 24, 2010
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II studyAlexandre Carpentier, Philippe Metellus, Renata Ursu, et al.
Journal of Neuro-Oncology|January 30, 2013
Interlaboratory comparison of IDH mutation detectionMartin J van den Bent, C Hartmann, Matthias Preusser, et al.
Brain Research|February 12, 2008
Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumorsAhmed Idbaih, Blandine Boisselier, Yannick Marie, et al.
Brain Pathology (Zurich, Switzerland)|August 21, 2016
Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomasFranck Bielle, François Ducray, Karima Mokhtari, et al.
Biomed Research International|May 8, 2014
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomasJulien Laffaire, Anna Luisa Di Stefano, Olivier Chinot, et al.
Acta Neuropathologica Communications|November 11, 2019
The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomasNathalie Grandin, Bruno Pereira, Camille Cohen, et al.
Neuro-Oncology|June 12, 2008
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomasAhmed Idbaih, Emmanuelle Crinière, Yannick Marie, et al.
Pageof 29

Showing results (171-180 of 290) with videos related to

Sort By:
Pageof 29
Neuro-Oncology|January 31, 2006
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastomaAlexandre Carpentier, Florence Laigle-Donadey, Sarah Zohar, et al.
Journal of Neuro-Oncology|June 15, 2019
Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastomaAntonin Dréan, Nolwenn Lemaire, Guillaume Bouchoux, et al.
International Journal of Cancer|December 14, 2007
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomasAhmed Idbaih, Yannick Marie, Carlo Lucchesi, et al.
Neuro-Oncology|March 24, 2010
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II studyAlexandre Carpentier, Philippe Metellus, Renata Ursu, et al.
Journal of Neuro-Oncology|January 30, 2013
Interlaboratory comparison of IDH mutation detectionMartin J van den Bent, C Hartmann, Matthias Preusser, et al.
Brain Research|February 12, 2008
Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumorsAhmed Idbaih, Blandine Boisselier, Yannick Marie, et al.
Brain Pathology (Zurich, Switzerland)|August 21, 2016
Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomasFranck Bielle, François Ducray, Karima Mokhtari, et al.
Biomed Research International|May 8, 2014
An ANOCEF genomic and transcriptomic microarray study of the response to irinotecan and bevacizumab in recurrent glioblastomasJulien Laffaire, Anna Luisa Di Stefano, Olivier Chinot, et al.
Acta Neuropathologica Communications|November 11, 2019
The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomasNathalie Grandin, Bruno Pereira, Camille Cohen, et al.
Neuro-Oncology|June 12, 2008
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomasAhmed Idbaih, Emmanuelle Crinière, Yannick Marie, et al.
Pageof 29